Abstract
Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Current Pharmaceutical Design
Title:Current Rapid-Onset Antidepressants and Related Animal Models
Volume: 24 Issue: 22
Author(s): Kuo Yan, Yi-Bing Chen, Jia-Rong Wu, Kuang-Dai Li and Yuan-Lu Cui*
Affiliation:
- Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No. 88 YuQuan Road, Nankai District, Tianjin, 300193,China
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Abstract: Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Export Options
About this article
Cite this article as:
Yan Kuo, Chen Yi-Bing , Wu Jia-Rong, Li Kuang-Dai and Cui Yuan-Lu *, Current Rapid-Onset Antidepressants and Related Animal Models, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180727115222
DOI https://dx.doi.org/10.2174/1381612824666180727115222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Legend in Neuroscience (1948-2018) Dr. Stephen D. Skaper, Ph. D
CNS & Neurological Disorders - Drug Targets Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Current Medicinal Chemistry A Comprehensive Review on the Ethnopharmacology, Phytochemistry, Pharmacology, and Toxicology of the Mandragora Genus; from Folk Medicine to Modern Medicine
Current Pharmaceutical Design RCAN1 Increases Aβ Generation by Promoting N-glycosylation via Oligosaccharyltransferase
Current Alzheimer Research Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) β-Secretase as a Therapeutic Target for Inhibitor Drugs
Current Medicinal Chemistry Can FreeSurfer Compete with Manual Volumetric Measurements in Alzheimer’s Disease?
Current Alzheimer Research Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets 4-(1-Adamantyl)phenylalkylamines with Potential Antiproliferative Activity
Letters in Organic Chemistry Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Multitarget Directed Ligand Approaches for Alzheimer’s Disease: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Current Pharmaceutical Design Evaluation of the Antipsychotic Effects of 2-(dimethylamino)- and 2-(methylamino)-7H-naphtho[1,2,3-de]quinolin-7-one Derivatives in Experimental Model of Psychosis in Mice
Current Topics in Medicinal Chemistry Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry The Blood-Central Nervous System Barriers Actively Control Immune Cell Entry into the Central Nervous System
Current Pharmaceutical Design